Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1409510 | 0.78 | FFAR4 (0.48) | NOTUMFFAR4DPP4IDO1PTGDR | |
| SCHEMBL1410358 | 0.73 | FFAR4 (0.48) | NOTUMFFAR4DPP4CCR2ACACB | |
| SCHEMBL1410615 | 0.71 | ACACB (0.45) | NOTUMFFAR4DPP4ACACB | |
| SCHEMBL1410200 | 0.70 | DPP4 (0.45) | NOTUMFFAR4DPP4ACACBADRB1 | |
| SCHEMBL1410206 | 0.69 | FFAR4 (0.65) | NOTUMFFAR4DPP4 | |
| SCHEMBL6498968 | 0.69 | NOTUM (0.62) | NOTUMFFAR4ADRB1 | |
| SCHEMBL1409363 | 0.69 | DPP4 (0.50) | NOTUMFFAR4DPP4ADRB1 | |
| SCHEMBL1409609 | 0.69 | DPP4 (0.50) | NOTUMFFAR4DPP4ADRB1 | |
| SCHEMBL1410372 | 0.69 | DPP4 (0.50) | NOTUMFFAR4DPP4ADRB1 | |
| SCHEMBL1409875 | 0.69 | FFAR4 (0.54) | NOTUMFFAR4DPP4ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | NES, BMI1, DOT1L | NOTUM 874/4885FFAR4 4589/4885DPP4 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.